CDF-Lyme™: A Composite Diagnostic Fingerprint for Lyme Disease and Post-Treatment Lyme-Associated Illness

A Multi-System Framework for High-Specificity Diagnosis

By Cynthia Adinig

Introduction: Why Lyme Disease Is Still Being Missed

Lyme disease is often treated as a straightforward tick-borne infection. In practice, it behaves as a multi-system condition shaped by infection persistence, immune variability, co-infections, and environmental exposure. While early detection frameworks work for a subset of patients, a significant portion present later with symptoms that are distributed across neurological, autonomic, inflammatory, and musculoskeletal systems.

These patients are rarely evaluated as a whole. Instead, symptoms are fragmented across specialties, with cognitive dysfunction sent to neurology, tachycardia to cardiology, pain to rheumatology, and fatigue often dismissed altogether. The result is a pattern recognition failure, not a lack of disease presence. Lyme-associated illness is frequently underdiagnosed, misclassified, or delayed due to this structural disconnect (Stanek et al., 2012; Steere et al., 2016).

Emerging clinical and patient-led data consistently show that Lyme disease is not a uniform condition, but a system-level disruption influenced by pathogen persistence, immune response variability, co-infections, treatment timing, and environmental exposures. This aligns with CYNAERA’s broader modeling work, which organizes Lyme into interacting domains rather than a single diagnostic category.

The Composite Diagnostic Fingerprint (CDF-Lyme™) was developed to address this gap. It translates Lyme disease into a structured, multi-domain diagnostic model that reflects how the condition actually presents in real-world patients.

What Is CDF-Lyme™?

CDF-Lyme™ is a composite diagnostic framework that evaluates Lyme disease through cross-system pattern recognition rather than single-test confirmation. Instead of asking whether a patient meets one narrow diagnostic threshold, the model assesses how strongly their clinical presentation aligns with a broader Lyme-associated illness pattern across multiple domains.

The framework is derived from CYNAERA’s Lyme Disease Phenotyping System, which organizes disease expression across ten core domains including infection burden, immune response, neurological involvement, autonomic instability, and structural modifiers. These domains reflect how symptoms cluster, evolve, and interact over time, rather than presenting as isolated findings.

CDF-Lyme™ translates these domains into a quantifiable diagnostic fingerprint. Each domain contributes weighted evidence based on signal strength, reliability, specificity, data completeness, and contextual modifiers such as co-infections or environmental exposure. This allows the model to identify disease patterns even when traditional testing is inconclusive or incomplete.

Importantly, CDF-Lyme™ is not designed as a replacement for existing diagnostics, but as a unifying framework that integrates fragmented clinical signals into a coherent structure. By doing so, it improves recognition of probable Lyme-associated illness and supports more consistent evaluation across clinical and research settings. CDF-Lyme™ is also designed to function upstream of treatment modeling. Within CYNAERA’s broader system, diagnostic fingerprinting informs phenotype-based intervention strategies, including remission-oriented approaches that depend on accurate classification of system state and disease architecture.

The Core Problem: Lyme as a Pattern Recognition Failure

Lyme disease is frequently underdiagnosed not because the condition is rare, but because its presentation is distributed across systems.

Patients often present with:

• cognitive impairment and neuroinflammatory symptoms

• autonomic instability including POTS-like features

• chronic fatigue and post-exertional worsening

• migratory musculoskeletal pain

• gastrointestinal and metabolic disruption

These features are typically evaluated in isolation. Without a system-level model, the overall disease pattern is missed. CDF-Lyme™ resolves this by converting multi-domain signals into a single diagnostic structure.

The 10 Core Domains of CDF-Lyme™

CDF-Lyme™ evaluates disease across ten interacting domains:

1. Infection Burden, Persistence, and Co-Infection Signal

2. Immune Response and Inflammatory Pattern

3. Neurocognitive and Neuroinflammatory Signal

4. Autonomic, Cardiovascular, and Circulatory Instability

5. Musculoskeletal and Connective Tissue Pattern

6. Gastrointestinal, Metabolic, and Nutritional Disruption

7. Hormonal and Endocrine Modulation

8. Sleep, Pain, and Neurological Excitability

9. Functional Severity and Disease Progression

10. Social, Structural, and Diagnostic Modifiers

These domains reflect real-world disease expression rather than isolated diagnostic criteria.

The CDF-Lyme™ Formula 

For a given patient p, the CDF-Lyme™ score is calculated across K domains:

CDF_Lyme(p) = Σ [ w_k · D_k(p) · R_k · S_k · U_k(p) · M_k(p) ]

Where:

• D_k(p) = Domain signal (strength of clinical presence from 0 to 1)

• R_k = Reliability (consistency across cohorts from 0 to 1)

• S_k = Specificity (ability to distinguish Lyme from other conditions from 0 to 1)

• U_k(p) = Usability of data (completeness and quality from 0 to 1)

• M_k(p) = Modifier term (co-infection load, environmental exposure, timing effects)

• w_k = Domain weight (relative importance, sum of all weights = 1)

Each domain produces a Domain Trust Score, and the final CDF-Lyme™ value is a weighted sum across all domains.

This structure ensures the model remains:

• interpretable for clinicians

• auditable for payers and regulators

• adaptable for incomplete data scenarios

Domain Trust Calculation

For each domain k:

T_k = D_k × R_k × S_k × U_k × M_k

Weighted contribution:

C_k = w_k × T_k

Final score:

CDF_Lyme(p) = Σ C_k

This approach allows Lyme disease to be identified through pattern coherence, not just severity within a single domain.

Interpretation Bands

• ≥ 0.75 → High-confidence Lyme-associated illness

• 0.50–0.74 → Probable Lyme pattern

• 0.30–0.49 → Partial or overlapping phenotype

• < 0.30 → Low likelihood of Lyme as primary driver

These thresholds support early identification even when testing is incomplete.

Diagnostic Fingerprint Calculation: Worked Example

Below is an illustrative example demonstrating how CDF-Lyme™ is applied in practice. Values are representative and designed to show how the model behaves under real-world conditions where data may be incomplete.

Patient Profile

• History of tick exposure in an endemic region

• Delayed diagnosis following initial flu-like illness

• Persistent fatigue, brain fog, and sensory sensitivity

• POTS-like symptoms including tachycardia and dizziness when standing

• Migratory joint and muscle pain

• Gastrointestinal disruption and food sensitivity

• Partial response to prior antibiotic treatment

• Environmental sensitivity, including symptom worsening in high humidity and mold exposure

Step 1: Domain Scoring

Each domain is scored across five parameters:

• D_k: Domain signal (0–1)

• R_k: Reliability (0–1)

• S_k: Specificity to Lyme (0–1)

• U_k: Usability of available data (0–1)

• M_k: Modifier (co-infection, environment, timing effects)

Example Domain Values

Domain	D_k	R_k	S_k	U_k	M_k	T_k (Product)	w_k	C_k (Contribution)
Infection & Co-Infection	0.90	0.88	0.92	0.75	0.90	0.493	0.14	0.0690
Immune / Inflammatory	0.75	0.80	0.85	0.65	0.85	0.266	0.10	0.0266
Neurocognitive	0.85	0.82	0.84	0.70	0.80	0.328	0.10	0.0328
Autonomic	0.92	0.90	0.88	0.85	0.88	0.480	0.12	0.0576
Musculoskeletal	0.80	0.78	0.80	0.70	0.85	0.297	0.10	0.0297
GI / Metabolic	0.70	0.75	0.78	0.65	0.80	0.213	0.08	0.0170
Endocrine	0.60	0.70	0.75	0.60	0.75	0.142	0.06	0.0085
Sleep / Neuro Excitability	0.78	0.80	0.82	0.70	0.82	0.293	0.08	0.0234
Functional Decline	0.88	0.85	0.80	0.90	0.90	0.485	0.12	0.0582
Structural Modifiers	0.90	0.88	0.78	0.95	0.92	0.568	0.10	0.0568

Step 2: Final Score Calculation

CDF_Lyme(p) = Σ C_k

Adding contributions:

0.0690

• 0.0266 = 0.0956

• 0.0328 = 0.1284

• 0.0576 = 0.1860

• 0.0297 = 0.2157

• 0.0170 = 0.2327

• 0.0085 = 0.2412

• 0.0234 = 0.2646

• 0.0582 = 0.3228

• 0.0568 = 0.3796

Final Score

CDF-Lyme(p) = 0.38

Interpretation

A score of 0.38 falls within the 0.30–0.49 range, indicating:

Partial or overlapping Lyme-associated phenotype

However, the model highlights strong signal concentration in:

• infection/co-infection domain

• autonomic instability

• functional decline

• structural diagnostic delay

This pattern suggests a high likelihood of Lyme-associated illness that has been partially captured but not fully validated through conventional testing.

Clinical Implications

Based on this fingerprint:

• Further evaluation for co-infections (Babesia, Bartonella) is recommended

• Autonomic testing should be prioritized

• Environmental factors (mold, humidity) should be assessed

• Stabilization strategies should begin before full diagnostic confirmation

This example demonstrates how CDF-Lyme™ identifies clinically meaningful patterns even when data is incomplete, reducing reliance on binary test results and improving early recognition of complex cases.

Why This Matters

Without a composite model, this patient would likely remain:

• partially diagnosed

• misclassified across specialties

• delayed in receiving targeted care

CDF-Lyme™ converts fragmented signals into a structured diagnostic fingerprint, enabling earlier and more accurate intervention.

Why This Model Is Different

Traditional diagnostic models rely on:

• binary test results

• isolated symptoms

• single-specialty evaluation

CDF-Lyme™ instead evaluates:

• cross-system interaction

• temporal variability

• environmental triggers

• structural barriers to diagnosis

This reflects how Lyme disease actually behaves in real patients.

Clinical and Research Applications

CDF-Lyme™ is designed for use across multiple settings:

Clinical Care

Supports earlier recognition and reduces diagnostic fragmentation

Research and Trials

Improves cohort stratification and signal detection

Public Health

Enhances prevalence estimation by capturing underdiagnosed populations

CYNAERA Integration

Works alongside SymCas™ (flare prediction), IACC Twin™ (simulation), and VitalGuard™ (environmental risk modeling)

Economic and System Impact

Lyme disease often leads to prolonged diagnostic pathways involving multiple specialties, redundant testing, and delayed treatment.

By introducing a structured diagnostic framework, CDF-Lyme™ has the potential to:

• reduce diagnostic timelines

• decrease unnecessary testing

• improve treatment targeting

• lower long-term disability burden

This aligns with CYNAERA’s broader Diagnostic Multiplier™ approach, which corrects for underdiagnosis and system inefficiencies.

Conclusion: Toward a New Diagnostic Standard

Lyme disease has remained difficult to diagnose not because it is rare or poorly understood, but because it has been approached through fragmented, single-system models that fail to capture its full complexity. Patients experience a distributed pattern of dysfunction across immune, neurological, autonomic, and metabolic systems, yet diagnostic frameworks have historically evaluated these signals in isolation.

CDF-Lyme™ introduces a structured alternative. By integrating multi-domain signals into a composite diagnostic fingerprint, it enables earlier recognition, improved stratification, and a more accurate representation of disease burden. This approach reflects how Lyme disease actually behaves, rather than how traditional models attempt to define it. This diagnostic structure also supports alignment with emerging intervention models. Within CYNAERA’s Lyme framework, remission-oriented approaches such as Personalized CRISPR Remission™ for Lyme, rely on accurate phenotype and system-state classification, which begins with models like CDF-Lyme™. When diagnosis is more precise, downstream treatment logic becomes more targeted and effective.

As healthcare systems move toward precision medicine, frameworks like CDF-Lyme™ will play a critical role in identifying complex, underrecognized conditions and ensuring that patients are no longer overlooked within clinical and research environments. The shift is not simply toward better testing, but toward better recognition of patterns that have always been present but rarely seen as a whole.

CYNAERA Framework Papers

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID,  ME/CFS  and CRISPR Remission Libraries are also in depth resources.

• Primary Chronic Trigger 

• VitalGuard™: Environmental Flare Risk Engine

• Corrected National Prevalence Estimates for (IACCs)

• Undercounted from Kabul to Kansas: The Hidden Men of IACC

• The Science of Remission of IACC's

• A Nobel-Scale Advance: AI-Powered CRISPR Platform for IACC's

• Personalized CRISPR Remission for Sarcoidosis

• Personalized CRISPR Remission for Lyme

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

​Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.

Licensing and Integration

CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.

Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.

About the Author 

Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.

Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.

Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™,  IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.

Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.

References

1. Stanek G, Wormser GP, Gray J, Strle F. 2012. Lyme borreliosis. The Lancet.https://doi.org/10.1016/S0140-6736(11)60103-7

2. Steere AC, Strle F, Wormser GP, et al. 2016. Lyme borreliosis. Nature Reviews Disease Primers.https://doi.org/10.1038/nrdp.2016.90

3. Kugeler KJ, Schwartz AM, Delorey MJ, et al. 2021. Estimating the frequency of Lyme disease diagnoses. Emerging Infectious Diseases.https://doi.org/10.3201/eid2702.202731